EDAP TMS in brief
EDAP TMS is a listed company in the Medical Equipment industry, based in France. Its last known market value was $200 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $71 M and a net loss of $29 M. Its largest product and service lines by sales in 2025 were Goods (69%), Spare parts and services (16%) and RPPs & leases (15%). By market, the largest shares of its 2025 sales came from USA (40%), Asia (28%) and France (7%). Its shares trade under the symbol EDA.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
EDAP TMS timeline
- 1997
- 🔔· approximateInitial public offering on Frankfurt
Events of EDAP TMS from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in France: #290 (Jan 2020) · #285 (Jan 2021) · #276 (Jan 2022) · #206 (Dec 2022) · #216 (Jul 2023) · #244 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -47.0%
- Operating margin
- -35.0%
- Return on equity
- -193.1%
- Liabilities / assets
- 75.4%
- Net debt
- $-2M
- Revenue growth
- +1.6%
- R&D / revenue
- 13.7%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $71M | +1.6% | $-25M | $-29M | -41.5% |
| Dec 2024 | $69M | +19.9% | $-22M | $-21M | -29.7% |
| Dec 2022 | $58M | +11.2% | $-4M | $-3M | -5.3% |
| Dec 2021 | $52M | +9.6% | $-2M | $1M | 1.6% |
| Dec 2020 | $48M | -5.5% | $0M | $-2M | -4.1% |
| Dec 2019 | $50M | +8.7% | $2M | $2M | 3.4% |
| Dec 2018 | $46M | +14.7% | $-2M | $-0M | -0.9% |
| Dec 2017 | $40M | — | $-2M | $-1M | -1.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-16M | — | — | $-0.78 | — |
| Dec 2024 | $-15M | — | — | $-0.55 | — |
| Dec 2022 | $-3M | — | — | $-0.09 | — |
| Dec 2021 | $5M | — | — | $0.02 | — |
| Dec 2020 | $2M | — | — | $-0.07 | — |
| Dec 2019 | $4M | — | — | $0.06 | — |
| Dec 2018 | $0M | $1M | $-1M | $-0.01 | — |
| Dec 2017 | $-3M | $1M | $-5M | $-0.02 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $10M (+25.5% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Aug 19, 20268-KCurrent reportOther events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportMaterial agreement
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 11, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- Jun 26, 20268-KCurrent reportBylaws amended · Shareholder vote
- Jun 1, 20268-KCurrent reportRegulation FD disclosure
- May 29, 20268-KCurrent reportOther events
- May 14, 2026DEF 14AProxy statement
- May 7, 202610-QQuarterly report · period to Mar 2026
Official filings of EDAP TMS with the US Securities and Exchange Commission.
Annual results
- Revenue
- $71 M
- Operating income
- $-25 M
- Net income
- $-29 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $79 M
- Total liabilities
- $60 M
- Total equity
- $19 M
As of December-2025
Insider trading at EDAP TMS#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David R. HornDirector | Buy | +10,000 | 4.750 | —local | 10,000 | Form 4 |
| filed | Fran SchulzDirector | Buy | +10,000 | 4.750 | —local | 15,100 | Form 4 |
| filed | Sanket ShahGeneral Counsel & Corp Sec | Buy | +5,000 | 4.750 | —local | 72,500 | Form 4 |
| filed | Steven AnnenSVP, Marketing & Product Mgmt. | Buy | +5,000 | 4.750 | 24 Klocal | 136,490 | Form 4 |
| filed | Kenneth S. MobeckChief Financial Officer | Buy | +5,000 | 4.750 | —local | 181,610 | Form 4 |
| filed | Ryan RhodesChief Executive Officer, Director | Buy | +21,000 | 4.750 | 100 Klocal | 626,649 | Form 4 |
| filed | Joshua LevineDirector | Buy | +10,000 | 4.750 | 48 Klocal | 45,000 | Form 4 |
| filed | Lance WillseyDirector | Buy | +50,000 | 4.750 | 238 Klocal | 1.29 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: EDAP TMS#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 234 shares at $4.23
- : 690 shares at $4.07
- : 529 shares at $4.22
- : 14 shares at $4.41
- : 946 shares at $4.18
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
EDAP TMS scorecard#
Passes 6 of the 11 checks that could be worked out: strongest in financial health (3 of 3), weakest in profitability (1 of 4). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 3
- ✓Revenue grew in the newest year1.6%Revenue up 1.6% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.78 vs -0.55Diluted EPS -0.78 in fiscal 2025 against -0.55 the year before (report's currency).
- ✗Net income higher than five years earlier-$29 M-$29 M in fiscal 2025 against -$2 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 4
- ✗Profitable in the newest year-$29 MNet income -$29 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median-35.0%-35.0% against Medical Equipment's median of -38.5% (8 companies).
- ✗Return on equity above 15%-94.5%-94.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-35.0%-35.0% in fiscal 2025 against -7.7% in 2022.
Financial health3 of 3
- ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.54 at the end of fiscal 2025.
- ✓Debt below equity0.9×Debt to equity 0.93 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $2 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year0.4%Diluted shares up 0.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Medical Equipment, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from EDAP TMS's statements, beside the median of Medical Equipment.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -35.0% | -38.5% | |
| Net margin | -41.5% | -44.9% | |
| Return on equity | -94.5% | -94.5% | |
| Revenue growth | 1.6% | 15.6% | |
| Debt to equity | 0.93× | — |
3of 9on the Piotroski tests of financial strength
- Net loss of $29 million.
- More cash than debt: net cash of $2 million.
EDAP TMS: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 · USD | FY 2024to Dec 31, 2024 · USD | FY 2023to Dec 31, 2023 · EUR | FY 2022to Dec 31, 2022 · EUR | FY 2021to Dec 31, 2021 · EUR | FY 2020to Dec 31, 2020 · EUR | FY 2019to Dec 31, 2019 · EUR | FY 2018to Dec 31, 2018 · EUR | FY 2017to Dec 31, 2017 · EUR | FY 2016to Dec 31, 2016 · EUR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 71+1.6%100% | 69—100% | 60+9.6%100% | 55+25.1%100% | 44+5.8%100% | 42−7.2%100% | 45+14.6%100% | 39+9.6%100% | 36+0.4%100% | 36—100% | |
| Cost of revenue | 41−0.3%57.5% | 41—58.6% | 36+16.5%59.6% | 31+20.6%56.1% | 26+10.1%58.2% | 23−2.6%55.9% | 24+7.4%53.2% | 22+6.3%56.8% | 21+9.1%58.6% | 19—53.9% | |
| Gross profit | 30+4.4%42.5% | 29—41.4% | 24+0.9%40.4% | 24+31.3%43.9% | 18+0.2%41.8% | 18−12.5%44.1% | 21+24.1%46.8% | 17+14.2%43.2% | 15−9.8%41.4% | 16—46.1% | |
| Research and development | 9.7+15.5%13.7% | 8.4—12.1% | 7.0+41.5%11.5% | 4.9+44.6%8.9% | 3.4−24.3%7.7% | 4.5+20.6%10.8% | 3.7−8.8%8.3% | 4.1+5.3%10.4% | 3.9+0.3%10.9% | 3.9—10.9% | |
| Selling and marketing | 27−0.2%38.7% | 27—39.4% | 23+38.1%37.4% | 16+52.6%29.7% | 11+15.7%24.4% | 9.3−14.5%22.3% | 11+2.8%24.2% | 11+10.8%26.9% | 9.5+7.6%26.6% | 8.9—24.9% | |
| General and administrative | 18+16.3%25.1% | 15—22.0% | 15+105%24.2% | 7.2+21.2%13.0% | 5.9+36.1%13.4% | 4.3+2.6%10.4% | 4.2+17.6%9.4% | 3.6+4.8%9.2% | 3.4+4.0%9.6% | 3.3—9.3% | |
| Operating expenses | 55+7.3%77.6% | 51—73.4% | 44+55.4%73.2% | 28+42.0%51.6% | 20—45.5% | — | — | — | 17+5.1%47.1% | 16—45.0% | |
| Operating income | −25—−35.0% | −22—−32.0% | −20—−32.8% | −4.3—−7.7% | −1.6−699%−3.7% | 0.3−87.8%0.6% | 2.2—4.9% | −1.3—−3.4% | −2.0−617%−5.7% | 0.4—1.1% | |
| Interest and finance income | 0.3−70.7%0.4% | 0.9—1.2% | 1.3+225%2.2% | 0.4—0.7% | — | — | — | — | — | — | |
| Interest expense and finance costs | 0.8+208%1.1% | 0.3—0.4% | 0.2+38.1%0.4% | 0.2+223%0.3% | 0.1−51.9%0.1% | 0.1−34.5%0.3% | 0.2+48.6%0.4% | 0.1+152%0.3% | 0.0−22.8%0.1% | 0.1—0.2% | |
| Net interest income | — | — | 1.1+357%1.8% | 0.2+62.8%0.4% | 0.1—0.3% | −0.1—−0.2% | −0.1−118%−0.3% | 0.8−69.8%2.0% | 2.6−33.1%7.4% | 3.9—11.1% | |
| Income before tax | −29—−40.8% | −20—−29.2% | −21—−34.0% | −2.1−335%−3.8% | 0.9—2.0% | −1.2−154%−2.9% | 2.2+10855%4.9% | 0.0—0.1% | −0.3−107%−0.8% | 4.4—12.5% | |
| Income tax | 0.4+39.9%0.6% | 0.3—0.5% | 0.6−23.1%1.1% | 0.8+334%1.5% | 0.2−62.6%0.4% | 0.5−24.0%1.2% | 0.7+89.7%1.5% | 0.4−7.7%0.9% | 0.4−35.5%1.1% | 0.6—1.7% | |
| Net income including minority interests | −29—−41.5% | −21—−29.7% | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −29—−41.5% | −21—−29.7% | −21—−35.0% | −2.9−519%−5.3% | 0.7—1.6% | −1.7r−1.7−213%−4.1% | 1.5r1.5—3.4% | −0.3r−0.3—−0.9% | −0.7r−0.7−118%−1.9% | 3.8—10.8% | |
| Earnings per share, basic | -0.78—— | -0.55—— | -0.57—— | -0.09−550%— | 0.02—— | -0.06−220%— | 0.05—— | -0.01—— | -0.02−114%— | 0.14—— | |
| Earnings per share, diluted | -0.78—— | -0.55—— | -0.57—— | -0.09−550%— | 0.02—— | -0.06−220%— | 0.05—— | -0.01—— | -0.02−115%— | 0.13—— | |
| Shares, weighted average (basic) | 37+0.4%— | 37—— | 37+7.6%— | 34+7.0%— | 32+10.2%— | 29+0.5%— | 29+0.1%— | 29+0.1%— | 29+4.1%— | 28—— | |
| Shares, weighted average (diluted) | 37+0.4%— | 37—— | 37+7.6%— | 34+6.1%— | 32+11.2%— | 29−1.6%— | 30+2.1%— | 29+0.1%— | 29−1.4%— | 29—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 20−34.0%25.9% | 31—34.7% | 43−31.1%47.5% | 63+33.8%62.4% | 47+91.1%61.1% | 25+18.2%44.7% | 21+7.3%39.4% | 19−2.7%39.9% | 20−9.0%42.7% | 22—47.2% | |
| Short-term investments | 0—0.0% | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | 0—0.0% | — | |
| Receivables | 15r21−22.6%18.9% | 19—21.6% | 18+33.1%19.5% | 13+23.5%13.3% | 11−3.9%14.1% | 11−0.2%20.5% | 11−4.7%21.3% | 12+5.4%24.4% | 11+23.3%24.0% | 9.1—19.6% | |
| Inventory | 7.8r13−59.6%9.8% | 19—21.5% | 15+28.3%16.5% | 12+57.1%11.6% | 7.5−6.1%9.7% | 8.0−2.3%14.5% | 8.2+13.4%15.4% | 7.2+7.0%14.8% | 6.7−16.1%14.4% | 8.0—17.2% | |
| Other current assets | 1.2r1.3−11.8%1.5% | 1.3—1.5% | 0.7−0.2%0.7% | 0.7+13.6%0.7% | 0.6+57.5%0.8% | 0.4−17.4%0.7% | 0.4+17.0%0.8% | 0.4−21.9%0.8% | 0.5+7.0%1.0% | 0.5—1.0% | |
| Current assets | 57−21.3%72.4% | 73—81.2% | 78−13.3%85.7% | 91+34.3%89.5% | 67+48.4%87.3% | 45+7.8%82.2% | 42+4.3%79.3% | 40+2.0%82.8% | 40−2.3%84.4% | 41r41—86.9% | |
| Property, plant and equipment | 9.9+30.6%12.5% | 7.6—8.5% | 5.9+57.2%6.4% | 3.7r4.2+3.5%3.7% | 3.6−2.3%4.7% | 3.7−9.0%6.7% | 4.1r3.1+36.0%7.7% | 3.0r4.2−18.8%6.1% | 3.7+32.9%7.9% | 2.8—5.9% | |
| Right-of-use (leased) assets | 2.0r3.1−25.6%2.5% | 2.7—3.0% | 1.7−3.5%1.9% | 1.8+14.7%1.8% | 1.6−17.9%2.0% | 1.9−28.4%3.4% | 2.6—5.0% | — | — | — | |
| Goodwill | 0.8r2.8−69.8%1.0% | 2.5—2.8% | 2.40.0%2.6% | 2.40.0%2.4% | 2.40.0%3.1% | 2.40.0%4.4% | 2.40.0%4.5% | 2.40.0%4.9% | 2.40.0%5.1% | 2.4—5.2% | |
| Other intangible assets | 1.8r1.8+59.2%2.3% | 1.1—1.3% | 1.1+49.5%1.2% | 0.7−0.4%0.7% | 0.7−4.3%0.9% | 0.8−1.2%1.4% | 0.8−9.1%1.5% | 0.8+60.7%1.7% | 0.5+254%1.1% | 0.1—0.3% | |
| Total assets | 79−11.6%100% | 89—100% | 92−9.5%100% | 101+30.9%100% | 77+39.9%100% | 55+4.0%100% | 53+8.9%100% | 49+3.9%100% | 47+0.7%100% | 47—100% | |
| Accounts payable | 12−10.1%14.8% | 13—14.6% | 11+69.2%12.3% | 6.6+20.5%6.6% | 5.5−3.5%7.1% | 5.7−5.4%10.3% | 6.0−4.0%11.4% | 6.3+1.1%12.9% | 6.2+11.8%13.3% | 5.6—11.9% | |
| Debt due within a year | 2.1r2.1−17.1%2.6% | 2.5—2.8% | 1.6−3.0%1.7% | 1.6+92.9%1.6% | 0.8−81.7%1.1% | 4.5+881%8.2% | 0.5−5.9%0.9% | 0.5+28.2%1.0% | 0.4+78.1%0.8% | 0.2—0.5% | |
| Current liabilities | 37−5.4%47.0% | 39—43.9% | 28+27.1%30.1% | 22+20.9%21.5% | 18−16.5%23.2% | 22+22.9%39.0% | 17+4.1%33.0% | 17+4.2%34.5% | 16+7.5%34.4% | 15—32.2% | |
| Long-term debt | 16+608%20.1% | 2.2—2.5% | 2.0−44.3%2.2% | 3.6−27.2%3.5% | 4.9+331%6.4% | 1.1+19.4%2.1% | 1.0−28.5%1.8% | 1.3+60.6%2.7% | 0.8+117%1.8% | 0.4—0.8% | |
| Lease liabilities (non-current) | 1.1r2.1−35.2%1.4% | 1.7—1.8% | 0.9−1.9%1.0% | 0.9+1.2%0.9% | 0.9−19.2%1.1% | 1.1−36.3%2.0% | 1.7—3.3% | — | — | — | |
| Total liabilities | 60+27.0%75.4% | 47—52.5% | 35+17.4%37.8% | 29+8.5%29.2% | 27−6.1%35.2% | 29+12.6%52.4% | 26+8.1%48.4% | 24+9.4%48.8% | 22−1.8%46.4% | 22—47.5% | |
| Retained earnings | −129—−163% | −99—−111% | −64—−69.4% | −42—−41.9% | −39—−51.1% | −40—−72.7% | −38—−72.4% | −40—−82.0% | −40—−84.5% | −39—−83.6% | |
| Shareholders' equity | 19−54.3%24.6% | 42—47.5% | 57−20.5%62.2% | 72+43.1%70.8% | 50+90.7%64.8% | 26−4.1%47.6% | 27+9.6%51.6% | 25−0.8%51.2% | 25+2.9%53.6% | 24—52.5% | |
| Total liabilities and equity | 79−11.6%100% | 89—100% | 92−9.5%100% | 101+30.9%100% | 77+39.9%100% | 55+4.0%100% | 53+8.9%100% | 49+3.9%100% | 47+0.7%100% | 47—100% | |
| Shares outstanding | 37+0.2%— | 37—— | 37+0.5%— | 37+10.3%— | 33+14.7%— | 29+0.1%— | 29+0.5%— | 290.0%— | 29+0.9%— | 29—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 3.4+22.7%4.8% | 2.8—4.0% | 1.9+19.2%3.2% | 1.6−16.4%2.9% | 1.9−8.8%4.4% | 2.1+12.0%5.1% | 1.9+16.7%4.2% | 1.6+2.4%4.1% | 1.6+53.5%4.4% | 1.0—2.9% | |
| Cash from operating activities | −16—−23.3% | −15—−21.2% | −15—−24.3% | −3.0−168%−5.5% | 4.4+125%10.1% | 2.0−48.0%4.7% | 3.8+2071%8.5% | 0.2—0.4% | −3.1−353%−8.6% | 1.2r1.1—3.4% | |
| Capital expenditure | — | — | — | — | — | — | — | −0.8—−2.1% | −1.0—−2.8% | −0.9r−0.9—−2.4% | |
| Intangible assets bought | −0.8—−1.2% | −0.2—−0.4% | −0.5—−0.9% | −0.1—−0.2% | −0.1—−0.2% | −0.1—−0.2% | −0.0—−0.1% | −0.4—−1.1% | −0.5—−1.3% | −0.2—−0.4% | |
| Cash from investing activities | −5.7—−8.1% | −4.5—−6.4% | −4.3—−7.2% | −2.4—−4.3% | −1.6—−3.7% | −2.0—−4.8% | −1.5—−3.4% | −1.6—−4.0% | −2.0—−5.7% | −0.4—−1.1% | |
| Debt issued | 12+344%17.6% | 2.8—4.0% | — | 0.3−73.0%0.5% | 1.1−78.2%2.4% | 4.8+605%11.6% | 0.7−33.3%1.5% | 1.0−37.0%2.6% | 1.6−48.3%4.6% | 3.2—8.9% | |
| Debt repaid | −2.7—−3.9% | −1.7—−2.4% | −1.6—−2.6% | −0.8—−1.5% | −1.4—−3.2% | −0.5—−1.2% | −1.1—−2.4% | −0.4—−1.1% | −0.2—−0.7% | −0.3r−0.2—−0.9% | |
| Shares issued | — | — | — | 22+3.2%39.8% | 21—48.3% | — | — | — | 0.5−91.2%1.5% | 6.2—17.4% | |
| Cash from financing activities | 8.6+71.7%12.2% | 5.0—7.2% | −0.9−104%−1.5% | 22+7.3%39.5% | 20+533%46.0% | 3.2—7.7% | −0.7−156%−1.5% | 1.2−59.0%3.0% | 2.9−62.2%8.0% | 7.6r7.7—21.4% | |
| Exchange-rate effect on cash | 3.0—4.2% | −2.9—−4.2% | — | — | −0.6−191%−1.3% | 0.6—1.5% | −0.2—−0.4% | −0.3−237%−0.8% | 0.2—0.7% | −0.0—−0.1% | |
| Change in cash | −11—−14.9% | −17—−24.6% | −20−223%−32.5% | 16−29.1%28.9% | 22+490%51.0% | 3.8+168%9.1% | 1.4—3.2% | −0.5—−1.4% | −2.0−124%−5.6% | 8.4—23.6% | |
| Report | 10-K | 10-K | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 9.8—100% | 13—100% | 18—100% | |
| Cost of revenue | 4.8—48.6% | 5.9—44.4% | 9.7—54.3% | |
| Gross profit | 5.1—51.4% | 7.3—55.6% | 8.1—45.7% | |
| Research and development | 2.5—25.0% | 2.3—17.5% | 2.6—14.6% | |
| Selling and marketing | 5.9—60.2% | 7.5—57.1% | 7.1—40.0% | |
| General and administrative | 4.5—45.4% | 5.5—41.8% | 5.8—32.5% | |
| Operating expenses | 13—131% | — | 16—87.1% | |
| Operating income | −7.8—−79.1% | −8.0—−60.8% | −7.4—−41.4% | |
| Income before tax | −5.3—−53.6% | −14—−109% | −8.9—−50.2% | |
| Income tax | 0.0—0.2% | 0.0—0.1% | 0.1—0.8% | |
| Income from continuing operations | −5.3—−53.8% | −14—−109% | — | |
| Income from discontinued operations | 0.8—8.4% | −0.1—−0.6% | — | |
| Net income including minority interests | −4.5*—−45.4% | −14*—−110% | −9.1—−51.0% | |
| Net income attributable to shareholders | −4.5—−45.4% | −14—−110% | −9.1—−51.0% | |
| Earnings per share, basic | -0.10—— | -0.39—— | -0.24—— | |
| Earnings per share, diluted | -0.10—— | -0.39—— | -0.24—— | |
| Shares, weighted average (basic) | 43—— | 38—— | 37—— | |
| Shares, weighted average (diluted) | 43—— | 38—— | 37—— | |
| Balance sheet | ||||
| Cash and cash equivalents | 56—50.8% | 22—28.9% | 15—20.8% | |
| Receivables | 10—9.2% | 10—13.5% | 20—27.3% | |
| Inventory | 8.3—7.5% | 8.3—11.1% | 13—18.5% | |
| Other current assets | 2.1—1.9% | 1.7—2.3% | 1.7—2.3% | |
| Current assets | 95—85.6% | 59—79.2% | 50—69.9% | |
| Property, plant and equipment | 9.1—8.2% | 8.6—11.6% | 10—14.2% | |
| Right-of-use (leased) assets | 1.4—1.2% | 1.5—2.0% | 2.8—3.9% | |
| Goodwill | 0.7—0.7% | 0.7—1.0% | 2.8—3.8% | |
| Other intangible assets | 1.8—1.6% | 1.8—2.4% | 1.7—2.4% | |
| Total assets | 111—100% | 75—100% | 72—100% | |
| Debt due within a year | 0.3—0.3% | 0.8—1.1% | 1.5—2.0% | |
| Current liabilities | 36—32.6% | 37—49.4% | 38—52.1% | |
| Long-term debt | 35—31.8% | 37—49.9% | 18—24.4% | |
| Lease liabilities (non-current) | 0.5—0.4% | 0.6—0.9% | 1.9—2.6% | |
| Total liabilities | 75—67.5% | 78—104% | 62—86.0% | |
| Retained earnings | −157—−141% | −152—−204% | −138—−191% | |
| Shareholders' equity | 36—32.5% | −3.2—−4.3% | 10—14.0% | |
| Total liabilities and equity | 111—100% | 75—100% | 72—100% | |
| Shares outstanding | 47—— | 38—— | 37—— | |
| Cash-flow statement | ||||
| Depreciation and amortization | 1.0*—10.2% | 1.0*—7.6% | 0.9—5.0% | |
| Cash from operating activities | −4.0*—−40.9% | −3.7*—−28.0% | −3.0—−16.7% | |
| Intangible assets bought | −0.2*—−1.6% | −0.2*—−1.2% | −0.0—−0.2% | |
| Cash from investing activities | −1.3*—−13.7% | −1.3*—−9.6% | −0.8—−4.2% | |
| Debt issued | 0*—0.0% | — | — | |
| Debt repaid | −0.5*—−5.4% | −0.6*—−4.5% | −0.6—−3.6% | |
| Shares issued | 43*—439% | — | — | |
| Cash from financing activities | 40*—410% | 12*—89.2% | −1.4—−7.7% | |
| Exchange-rate effect on cash | −0.2*—−2.1% | −0.3*—−2.2% | −0.3—−1.9% | |
| Change in cash | 35*—353% | 6.5*—49.5% | −5.4—−30.5% | |
| Report | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What EDAP TMS sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Goods$49 M69%+2.6%
- Spare parts and services$11 M16%-16%
- RPPs & leases$10 M15%+25%
Business segments
- High Intensity Focused Ultrasound (HIFU)$37 M53%+45%
- DISTRIB Division$26 M36%-24%
- Lithotripsy (ESWL)$7 M11%-23%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where EDAP TMS operates: 6 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇫🇷 France | Headquarters1 subsidiary | $5 M6.5% |
| 🇩🇪 Germany | 1 subsidiary | — |
| 🇯🇵 Japan | 1 subsidiary | — |
| 🇲🇾 Malaysia | 1 subsidiary | — |
| 🇨🇭 Switzerland | 1 subsidiary | — |
| 🇺🇸 USA | 1 subsidiary | $29 M40% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at EDAP TMS#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Rhodes | $1.7 M | $2.7 M | $860 K | $62 |
| 2024Chief executive | $1.3 M | $769 K | $738 K | $42 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at EDAP TMS#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Material agreement 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| New debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
How EDAP TMS compares in Medical Equipment
- Revenue$71 M · higher than 33% of 19
- Net margin-47.0% · higher than 19% of 17
- Revenue growth1.6% · higher than 25% of 13
- 🇺🇸 Avita Medical, Inc.$525 M
- 🇺🇸 Electromed, Inc.$341 M
- 🇺🇸 TELA Bio, Inc.$52 M
- 🇺🇸 Fonar Corporation$86 M
- 🇺🇸 IRIDEX Corporation$12 M
- 🇬🇧 Medica Group Limited$95 M
Peer comparison · Medical Equipment
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| EDAP TMS🇫🇷 | $200 M | — | -47.0% | +1.6% |
| Avita Medical, Inc.🇺🇸 | $525 M | — | -42.6% | +11.5% |
| Viemed Healthcare, Inc.🇺🇸 | $367 M | 23.5× | 5.0% | +20.5% |
| Electromed, Inc.🇺🇸 | $341 M | 28.6× | 15.8% | +15.3% |
| Profound Medical Corp.🇨🇦 | $240 M | — | -137.4% | +50.8% |
| Streamex Corp.🇺🇸 | $52 M | — | — | +100.0% |
| TELA Bio, Inc.🇺🇸 | $52 M | — | -53.6% | +15.8% |
| IRIDEX Corporation🇺🇸 | $12 M | — | -6.9% | +8.2% |
| Beyond Air, Inc.🇺🇸 | $4 M | — | -407.6% | +107.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Avita Medical, Inc.$525 M
- Viemed Healthcare, Inc.$367 M
- Electromed, Inc.$341 M
- Profound Medical Corp.$240 M
- Streamex Corp.$52 M
- TELA Bio, Inc.$52 M
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at EDAP TMS? Verify and update this profile — free
Show EDAP TMS's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.